Baidu
map

皮肤与性病指南

订阅

MedSci主页 / 所有栏目 / 皮肤与性病指南

2020 欧洲指南：寻常型银屑病的系统治疗—第1部分：治疗和监测建议

2020-11-30 欧洲皮肤病与性病学会 J Eur Acad Dermatol Venereol . 2020 Nov;34(11):2461-2498.

银屑病

欧洲寻常型银屑病的系统治疗指南主要依据EuroGuiDerm指南和共识声明制定手册制定。本文为该指南的第1部分，主要内容涉及寻常型银屑病的系统治疗和监测建议。

中文标题：

2020 欧洲指南：寻常型银屑病的系统治疗—第1部分：治疗和监测建议

英文标题：

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations

发布机构：

欧洲皮肤病与性病学会

发布日期：

2020-11-30

简要介绍：

欧洲寻常型银屑病的系统治疗指南主要依据EuroGuiDerm指南和共识声明制定手册制定。本文为该指南的第1部分，主要内容涉及寻常型银屑病的系统治疗和监测建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 欧洲指南：寻常型银屑病的系统治疗—第1部分：治疗和监测建议.pdf)] GetToolGuiderByIdResponse(projectId=1, id=bc51f1c0020302d3, title=2020 欧洲指南：寻常型银屑病的系统治疗—第1部分：治疗和监测建议, enTitle=EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations, guiderFrom=J Eur Acad Dermatol Venereol . 2020 Nov;34(11):2461-2498., authorId=0, author=, summary=欧洲寻常型银屑病的系统治疗指南主要依据EuroGuiDerm指南和共识声明制定手册制定。本文为该指南的第1部分，主要内容涉及寻常型银屑病的系统治疗和监测建议。, cover=https://img.medsci.cn/20201227/1609071951644_2020535.jpg, journalId=0, articlesId=null, associationId=1016, associationName=欧洲皮肤病与性病学会, associationIntro=EADV is a non-profit association, founded in 1987, whose mission is to advance excellence in clinical care, research, education and training in the field of dermatology and Venereology and to act as the advocate and educator of patients particularly those with cutaneous or venereal diseases., copyright=0, guiderPublishedTime=Mon Nov 30 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>欧洲寻常型银屑病的系统治疗指南主要依据EuroGuiDerm指南和共识声明制定手册制定。本文为该指南的第1部分，主要内容涉及寻常型银屑病的系统治疗和监测建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=4418, tagName=银屑病)], categoryList=[CategoryDto(categoryId=39, categoryName=皮肤与性病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=4418, guiderKeyword=银屑病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5062, appHits=103, showAppHits=0, pcHits=767, showPcHits=4959, likes=0, shares=4, comments=4, approvalStatus=1, publishedTime=Sun Dec 27 22:03:53 CST 2020, publishedTimeString=2020-11-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Dec 27 20:26:03 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 16:20:39 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 欧洲指南：寻常型银屑病的系统治疗—第1部分：治疗和监测建议.pdf)])
2020 欧洲指南：寻常型银屑病的系统治疗—第1部分：治疗和监测建议.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1066981, encodeId=945e106698103, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd875691647, createdName=ms9000000291054786, createdTime=Thu Nov 04 16:49:39 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051859, encodeId=ce6b105185977, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:32:00 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911592, encodeId=541b91159271, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=662f5447666, createdName=ms2000000031915985, createdTime=Mon Dec 28 12:59:12 CST 2020, time=2020-12-28, status=1, ipAttribution=)]
    2021-11-04 ms9000000291054786

    好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1066981, encodeId=945e106698103, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd875691647, createdName=ms9000000291054786, createdTime=Thu Nov 04 16:49:39 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051859, encodeId=ce6b105185977, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:32:00 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911592, encodeId=541b91159271, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=662f5447666, createdName=ms2000000031915985, createdTime=Mon Dec 28 12:59:12 CST 2020, time=2020-12-28, status=1, ipAttribution=)]
    2021-09-16 湘雅科教

    受益匪浅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1066981, encodeId=945e106698103, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd875691647, createdName=ms9000000291054786, createdTime=Thu Nov 04 16:49:39 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051859, encodeId=ce6b105185977, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:32:00 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911592, encodeId=541b91159271, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=662f5447666, createdName=ms2000000031915985, createdTime=Mon Dec 28 12:59:12 CST 2020, time=2020-12-28, status=1, ipAttribution=)]
    2020-12-28 ms2000000031915985

    赞赞赞

    0

相关指南

2020 BAD指南：银屑病生物治疗

英国皮肤科医师协会(BAD,British Association of Dermatologists) · 2020-03-18

中国银屑病生物治疗专家共识（2019）

中华医学会皮肤性病学分会 · 2019-12-30

生物反馈疗法调治银屑病专家共识（2019）

中国皮肤性病相关专家小组（统称） · 2019-09-02

2019 CDA实践指南：生物制剂治疗银屑病

国外皮肤性病相关专家小组（统称） · 2019-02-20

2019 AAD/NPF指南：银屑病伴意识和注意力合并症的管理的治疗

美国皮肤病学会(AAD,American Academy of Dermatology) · 2019-02-07

2019 AAD/NPF指南：应用生物制剂治疗银屑病

美国皮肤病学会(AAD,American Academy of Dermatology) · 2019-02-07

拓展阅读

银屑病及银屑病性关节炎的指南：第5部分.银屑病的光疗及光化学疗法的治疗指南（AAD 2010）

美国皮肤病学会(AAD,American Academy of Dermatology) · 2010-01-01

2010 银屑病关节炎诊断及治疗指南

中华医学会风湿病学分会(CRA,Chinese Rheumatology Association) · 2010-09-01

银屑病及银屑病性关节炎的指南：第6部分.关于银屑病及银屑病性关节炎的治疗指南：基于病例及研究的结论（AAD 2011）

美国皮肤病学会(AAD,American Academy of Dermatology) · 2011-02-07

2011 EULAR共识：银屑病关节炎的药物治疗

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2011-09-27

2012 寻常性银屑病的常用外用药物治疗共识

中华医学会皮肤性病学分会 · 2012-04-30

2012 BSR/BHPR指南：应用生物制剂治疗银屑病关节炎

英国风湿病学会(BSR,British Society for Rheumatology) · 2013-07-25

Baidu
map
Baidu
map
Baidu
map